Skip to Content
Event BSC congress 2027 starts on 28 Jan 2027, 09:00:00 (Europe/Brussels)
S13 - Symposium: How to optimize cardiometabolic health in obesity and type 2 diabetes with semaglutide?
Symposium
Location: Room Folon - 28/01/2027, 15:10 - 28/01/2027, 16:25 (Europe/Brussels) (1 hour 15 minutes)
Moderator:
Jean-Baudouin Van Leeuw - GhdC de Charleroi
Wilfried Mullens - ZOL Genk

15:10 - 15:15, Intro by moderators 

15:15 - 15:30, Understanding the obesity epidemic : biology, environment and policy
Prof. Dr. Wilfried Mullens is a cardiologist and heart failure specialist at Ziekenhuis Oost-Limburg in Genk, Belgium, and Professor of Cardiovascular Physiology at Hasselt University. He completed his training in Cardiology and Cardiac Rehabilitation in Belgium in 2005, followed by advanced fellowships in Heart Failure and Cardiac Transplantation (2007) and Electrical Therapies for Heart Failure (2008) at the Cleveland Clinic in Ohio, USA. In 2009, he obtained his PhD from Eindhoven University of Technology in the Netherlands.

His clinical and research work focuses on heart failure, with particular expertise in congestion and cardiorenal interactions, diuretic therapy, and cardiac resynchronization therapy. He has authored or co-authored more than 400 scientific publications and has an extensive track record in translational and clinical heart failure research. He was the principal investigator of the ADVOR trial (Acetazolamide in Decompensated Heart Failure with Volume Overload), a landmark randomized, double-blind trial in acute heart failure published in The New England Journal of Medicine.

Prof. Mullens previously served as President of the Belgian Working Group on Heart Failure and is currently President of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).







15:30 - 15:50, What about the role of incretin mimetics in the new ESC HF guidelines?

Biography





15:50 - 16:10, Why does the CKM syndrome matters to cardiologists?

Pieter Martens is a cardiologist and heart failure specialist at ZOL Genk. His special focus is on invasive hemodynamic evaluation of heart failure, hypertrophic cardiomyopathy. From 2021-2023 he trained at the Cleveland Clinic as advanced heart failure and mechanical circulatory support fellow. He has a 10% ZAP mandate at the Uhasselt as co-director of the Limburg Clinical Research Center. Pieter Martens has a master in clinical trials from Oxford University and is active within the Clinical Trial Unit of ZOL Genk.





16:10 - 16:25, Q&A